Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.
The Biotechnology Industry Organization and the Delaware BioScience Association last week commended the Delaware State Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
AssistRx last week introduced a new technology that simplifies the prescribing of specialty therapies while streamlining communications between prescribers, pharmacies, patients and manufacturers. It’s smart technology that can lead to patients receiving specialty medications weeks earlier than ever before, the company claimed.
Rite Aid on Tuesday announced it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accreditation organization that establishes quality standards for the healthcare industry.
Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis.
OncologyRx Care Advantage, McKesson Specialty Health’s oral oncology products specialty pharmacy, on Monday announced that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.
Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.